List view / Grid view
Stem cells are undifferentiated biological cells that can differentiate into specialised cells and can divide to produce more stem cells.
The human body has an incredible ability to repair itself, both from acute trauma and chronic damage that accumulates as we age. Here, Cameron Lee, Principal Scientist at Tune Therapeutics, reveals the potential of harnessing the body’s natural regenerative capabilities with epigenetic control of stem cells.
New insights into the role of SUMOylation in the brain could lead to new targeted therapies for neurodegenerative conditions.
Developing cell therapies solely with healthy donor material can jeopardise clinical outcomes, introducing risks ranging from faulty preclinical data to manufacturing failures. We spoke to Priya Baraniak, CBO at OrganaBio, who advocates for early integration of diseased donor material, improved biobanking infrastructure, and cross-industry collaboration to develop more effective, patient-relevant…
Findings show that alpha-synuclein and an immune response are required for Lewy body formation, in an effect specific to dopaminergic neurons.
By studying organoids derived from adult stem cells, researchers made a discovery that could improve the development of personalised therapeutics.
Cincinnati Children’s have repaired damaged intestines in a rodent model, moving research efforts closer to clinical trials.
Understanding the signalling pathway controlling neural stem cell reactivation could offer a strategy for using existing drugs to treat neurodevelopmental disorders.
31 July 2024 | By bit.bio
Watch this webinar to discover the latest astrocyte research and its implications for CNS drug discovery.
The agreement between Cartherics, The University of Sydney and The University of Queensland will further stem cell-derived heart muscle therapy for heart failure.
Blocking the TGF-β signalling pathway produced effective antitumour activity against hepatocellular carcinoma.
The hiPSC-derived skeletal muscle model is the first to uncover the biological mechanisms underlying loss of mobility.
In this episode, we discuss how new insights into stem cell biology are leading to novel therapeutics in regenerative medicine beyond cell therapy.
We had the privilege of interviewing Brian Culley, CEO of Lineage Cell Therapeutics. He discusses how Lineage’s pluripotent stem cell platform is extraordinarily advantageous, details two early-stage programmes addressing auditory and vision disorders and reveals how Lineage is choosing to target conditions that will make a real difference.
The development of a new membrane which better mimics human extracellular membranes will enable more accurate disease research.
Topological defects in mesenchymal stromal cell self-assembly could suggest their potential for cartilage regeneration.
